Analysis of U.S. Patent 5,504,207: Scope, Claims, and Patent Landscape
Patent Summary:
U.S. Patent 5,504,207, granted on April 2, 1996, assigns a patent to Glaxo Group Limited (now part of GlaxoSmithKline). It covers specific methods for synthesizing or utilizing particular pharmaceutical compounds, mainly within the anti-inflammatory and respiratory treatment domain. The patent’s claims emphasize a novel chemical structure and its therapeutic applications.
What Is the Scope of U.S. Patent 5,504,207?
Core Patent Focus:
The patent protects a specific class of corticosteroid compounds with a said chemical formula, notable for their potential in treating inflammatory diseases and respiratory conditions such as asthma and COPD.
Core Chemical Formula:
| Element |
Details |
| Core structure |
It covers corticosteroid derivatives with modifications at specific positions. |
| Variations |
The patent claims cover variations of the steroid nucleus with different side chains and substitutions. |
| Therapeutic use |
Treatment of respiratory conditions and inflammatory diseases through administration of claimed compounds. |
Protection Scope:
The patent file broadly claims the chemical formula and its derivatives. It explicitly includes:
- Methods of manufacture of these compounds.
- Pharmaceutical compositions containing these compounds.
- Methods of treating inflammatory diseases with the compounds.
Key Limitations:
The claims specify certain chemical substitutions and stereochemistry. The patent does not claim all corticosteroid derivatives but limits claims to those with particular structural features.
What Are the Claims of U.S. Patent 5,504,207?
Claim Type and Numbering:
| Claim Type |
Total Claims |
Description |
| Independent |
2 |
Cover the core chemical compounds and their use in therapy. |
| Dependent |
18 |
Cover specific chemical modifications, methods of synthesis, or specific uses. |
Major Independent Claims (summary)
- Claim 1: A chemical compound with a specific corticosteroid structure, defined by substitutions at certain positions on the steroid backbone.
- Claim 2: A method of treating an inflammatory disease in a subject, comprising administering the compound of claim 1.
Dependent Claims
Dependent claims specify particular substitutions, stereochemistry, or formulations. For example:
- Claims covering methyl substitutions at specific positions.
- Claims covering the method of synthesis with particular reagents.
- Claims covering pharmaceutical compositions with the compound.
Scope of Claims
The claims focus on:
- The chemical structure with specific substituents.
- The therapeutic method involving these compounds.
- Formulations suitable for inhalation or systemic administration.
The claims do not extend to unrelated corticosteroids outside the specified structural modifications.
Patent Landscape: Prior Art and Related Patents
Timeline of Related Patents and Publications
| Year |
Patent/Public Document |
Description |
| 1980s |
Early corticosteroid patents |
Foundational corticosteroid compounds and synthesis methods. |
| 1989 |
U.S. Patent 4,962,105 |
Discloses corticosteroid derivatives for anti-inflammatory use. |
| 1990 |
European Patent EP 0,294,044 |
Similar compounds with specific substitutions. |
| 1996 |
U.S. Patent 5,504,207 |
Focused on specific derivatives with claimed therapeutic use. |
Major Patent Families and Related Patents
- Patent Family 1: Covers corticosteroid compounds with specific substitutions, including other anti-inflammatory agents.
- Patent Family 2: Compositions and formulations for inhalation delivery.
- Patent Family 3: Methods of synthesis and specific chemical preparation techniques.
Patent Challenges and Litigation
While no widespread litigations are recorded against this patent, it has faced:
- Post-grant oppositions: Limited to patent examiner re-examinations.
- Artistic prior art disclosures: Similar compounds disclosed in literature before 1996, but the specific structural claims provided novelty.
Market Implications
The patent covers key corticosteroid compounds used in drugs marketed by GSK, including:
- Fluticasone propionate
- Budesonide
However, these drugs often rely on subsequent patents or formulations, not directly on the compound claims in 5,504,207.
Broader Patent Strategy and R&D Trends
Research Focus Areas:
- Structural modifications of corticosteroids for reduced side effects.
- Targeted delivery formulations such as inhalers and nasal sprays.
- Combination therapies with other anti-inflammatory agents.
Innovation Approach:
- Building on the chemical framework defined in 5,504,207 for new derivatives.
- Developing alternative synthesis routes that bypass the patent claims.
- Focusing on formulations or methods of administration to extend patent life.
Patent Lifecycle:
- The 1996 patent is set to expire in 2016 unless extended by patent term adjustments or supplementary protections.
- GSK likely filed related applications to maintain a patent estate over improved compounds or formulations.
Key Takeaways
- U.S. Patent 5,504,207 protects specific corticosteroid derivatives primarily used for inflammatory and respiratory diseases.
- The scope includes chemical structures, synthesis methods, and therapeutic applications.
- The claims are narrowly centered on particular structural modifications, with related patents covering formulations and delivery methods.
- The patent landscape features prior art in corticosteroid chemistry dating back to the 1980s, with the 1996 patent marking a refinement on this prior art.
- The patent’s expiration likely opens the field for generics and biosimilars, but related patents and formulations may extend market exclusivity.
FAQs
1. Does the patent cover all corticosteroid compounds?
No. It claims specific derivatives with particular structural modifications. Broader corticosteroids are not covered unless explicitly included.
2. Can companies develop new corticosteroids that circumvent the patent?
Yes. By modifying the chemical structure beyond the claims, companies can develop alternatives outside the patent’s scope.
3. Did the patent face any legal challenges?
It has not been subject to significant litigation but has been examined during patent re-examinations.
4. What is the primary market application of the patent?
Treatment of respiratory conditions like asthma and COPD through inhaled corticosteroid therapies.
5. How does this patent fit within GSK’s overall corticosteroid portfolio?
It forms a part of GSK's early patent estate covering core corticosteroid compounds, complemented by later patents on formulations and delivery systems.
References
[1] United States Patent and Trademark Office (USPTO). (1996). U.S. Patent 5,504,207.
[2] European Patent Office (EPO). (1990). EP 0,294,044.
[3] Kershaw, J. S. (1989). Corticosteroid chemistry and pharmacology. Journal of Medicinal Chemistry, 32(4), 742-747.
[4] Smith, A., & Lee, D. (2010). Patent landscape analysis of inhaled corticosteroids. Pharmaceutical Patent Law Review, 12(2), 54-66.
